T he 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, or statins, are potent inhibitors of cholesterol biosynthesis that are extensively used in the treatment of hypercholesterolemia (1) . Several studies have demonstrated the beneficial effects of statins in reducing cardiovascular-related morbidity and mortality in patients with and without coronary artery disease (1, 2) . More recently, it has been suggested that statins may confer renoprotection in a variety of glomerular diseases, including diabetic nephropathy, through their lipidlowering properties (3, 4) . It is usually assumed that the beneficial effects of statins result from the competitive inhibition of cholesterol synthesis. However, by inhibiting the synthesis of L͗-mevalonic acid, statins may also exert additional beneficial effects by preventing the synthesis of various isoprenoids, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP; ref. 5) . Both FPP and GGPP are important lipid attachments for the posttranslational modifications of a variety of small GTPase proteins, such as Ras and Rho GTPases (6) .
Recent studies suggest that some of the cholesterol-independent or ''pleiotropic'' effects of statins are mediated via small GTPases (7, 8) .
By cycling between inactive GDP-and active GTP-bound states, small GTPase proteins function as critical relays in the transduction of signals emanating from membrane receptors. Among the small GTPases, the Ras and Rho family of proteins hierarchically and͞or coordinately regulate various cellular processes such as apoptosis, differentiation, and cellular proliferation (9, 10) . The role of GTPases in the high glucose (HG)-mediated proliferation of glomerular mesangial cells (MCs), an early feature of diabetic nephropathy, has not been previously elucidated. We hypothesize that the possible beneficial effect of statins in diabetic nephropathy is independent of its antihyperlipidemic effect, and is mediated by reversing the up-regulation of Rho GTPases.
Several in vivo studies have recently unraveled the significance of MC proliferation in the early stages of diabetic nephropathy (11, 12) . It seems that mesangial hypercellularity precedes an increase in the extracellular matrix proteins and glomerular sclerosis, hallmarks of diabetic nephropathy. Moreover, in vitro studies have indicated that HG ambience stimulates MC proliferation and extracellular matrix expansion (13, 14) . However, the precise molecular mechanism of this hyperplastic phenotype at the cell-cycle level has not been previously explored. Cell-cycle progression is regulated by the activity of the cyclin-dependent kinases (CDK), which consist of a kinase core and an associated cyclin subunit (15) . In the early G 1 phase of the cell cycle, the D-type cyclins activate CDK4 and CDK6 as cells leave the quiescent phase. CDK2 complex forms later as cells prepare to begin DNA synthesis. The activities of the CDK family are not only controlled by positive regulators, or cyclins, but are also under negative control of a number of different CDK inhibitors (16) . The latter bind to specific cyclin-CDK complexes and inhibit their activities. The CDK inhibitors are classified on the basis of their sequence homology and substrate specificity. Two families of CDK inhibitors have been identified (16) . The CDK inhibitor p21, a 21-kDa protein, is a member of the CIP͞KIP family. The protein levels of p21 are low in most quiescent cells. However, p21 protein levels increase during cell proliferation (17) . Recent studies have shown that p21 can inhibit cell Abbreviations: HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; CDK, cyclin-dependent kinase; HG, high glucose; MC, mesangial cell; NG, normal glucose.
proliferation by inhibiting CDKs or by a direct inhibitory effect on the proliferating cell nuclear antigen (16, 17) .
The purpose of this study is to determine the role of isoprenoid intermediates and cell-cycle regulatory proteins in the HGinduced proliferation of glomerular MCs and the modulatory effects of simvastatin during cell cycle progression.
Materials and Methods
Cell culture media and supplies were purchased from Life Technologies (Grand Island, NY). Simvastatin was obtained from Merck Sharp & Dohme. Mevalonate, FPP, and GGPP were purchased from Sigma. Simvastatin prodrug was activated to its active form, as described (18) . Mevalonate was chemically activated by alkaline hydrolysis (18) . The antibody detection kit (chemiluminescence) and the nylon nucleic acid membrane (Hybond) were purchased from Amersham Pharmacia. RhoA mutants were kindly provided by Jacob Sznajder (Northwestern University, Chicago, IL).
Cell Culture. Glomeruli were isolated from rat kidneys, and isolated MCs were maintained in a DMEM (DMEM͞F12, Invitrogen), supplemented with 10% heat-inactivated FBS, in the presence of a humidified 5% CO 2 incubator at 37°C. The cells used in these experiments were from 5th-15th passages. The MCs were rendered quiescent by incubation in the serum-free medium for 48 h, and the trypan blue exclusion test was used to monitor the viability of cells. For each experiment, cultured MCs were placed in DMEM containing low glucose (5 mM glucose), high glucose (30 mM glucose), and high glucose with simvastatin. In experiments with simvastatin, the cells were preincubated with simvastatin for 24 h before high-glucose exposure. (1 Ci͞ml; 1 Ci ϭ 37 GBq) was added, and the cells were incubated for an additional 24 h. Then, they were processed for determination of incorporated radioactivity after TCA precipitation.
Western Blotting. The quiescent rat glomerular MCs were washed with PBS and microcentrifuged for 15 min at 1,500 ϫ g at 15 C. For preparation of whole-cell lysate, the pellet was resuspended in 300 l of lysis buffer (50 mM Tris⅐HCl, pH 7.4͞150 mM NaCl͞25 mM EDTA͞5 mM EGTA͞0.25% sodium deoxycholate͞1 mM DTT͞1 mM sodium fluoride͞0.1 mg/ml PMSF͞2 g/ml leupeptin͞0.234 trypsin inhibitor unit (TIU)/ml aprotinin͞1 g/ml pepstatin A). For preparation of plasmalemmal proteins, membrane fractions were first purified as described (12) . Briefly, the cells were washed with PBS and resuspended in 10 mM Tris⅐HCl, pH 7.4͞10 mM NaCl͞1.5 mM MgCl 2 ͞0.02 mM PMSF, and homogenized in a Dounce homogenizer. The homogenate was centrifuged at 1,000 ϫ g for 10 min. The supernatant was overlaid on 35% sucrose solution and centrifuged for 60 min at 18,000 ϫ g. The membrane fraction at the interface was removed and resuspended in 10 mM Tris⅐HCl, pH 7.4͞250 mM sucrose (buffer A). The sample then was centrifuged, and the pellets were resuspended in buffer A and stored at 4°C. Finally, the protein concentration in the total cell lysate and plasmalemmal fractions were measured by Bradford assay. Equal amounts of protein (50 g) from different variables were subjected to SDS͞PAGE analysis and then electroblotted onto nylon membranes. The blots then were individually probed with anti-p21, anti-p27 (PharMingen), anti-cyclin D1 and anti-cyclin A (Santa Cruz Biotechnology), and anti-pan-Ras and anti-Rho antibodies (Upstate Biotechnology, Lake Placid, NY) in Trisbuffered saline containing 0.5% Tween 20; autoradiograms were prepared by using an enhanced chemiluminescence system. CDK Assay. The CDK assay was performed as described (19) . Briefly, cell protein extracts were prepared by lysis in Hepes buffer (50 mM Hepes, pH 7.0͞150 mM NaCl͞0.2 mM PMSF͞ 100 M sodium orthovanadate͞10 mM ␤-glycerophosphate͞1 mM sodium fluoride͞0.33 TIU/ml aprotinin). After preclearing the protein extract (200 g) with 30 l of protein A agarose, immunoprecipitation was carried out with 3 g of anti-CDK4 or anti-CDK2 (Santa Cruz Biotechnology) for 1 h at 4°C. CDK4 kinase activity in the immunoprecipitates was determined by using retinoblastoma protein as a substrate, whereas CDK2 kinase activity was determined by using histone H1 as the substrate (Santa Cruz Biotechnology). Immune complexes were resuspended in 35 l of kinase buffer containing 1 g of glutathione S-transferase retinoblastoma (GST-Rb) (or histone H1), 1 M cold ATP, 0.5 mCi͞ml [␥ 32 P]ATP (Amersham Pharmacia), 50 mM Tris⅐HCl, 10 mM MgCl 2 , and 1 mM DTT; incubation was carried out for 30 min at 30°C, and the reaction was terminated by heating at 95°C for 5 min. Phosphorylated products were analyzed by SDS͞10% PAGE, and autoradiograms were prepared.
RhoA Mutant Transfection. MCs were seeded on cover glasses placed into six-well dishes. Cells cultured in HG (30 mM) media were transfected with 5 g of pcDNA3-wtRhoA (wild type RhoA) or pcDNA3-N19RhoA (dominant-negative RhoA mutant) by using Lipofectamine (Life Technologies) following manufacturer's instructions. Transfected MCs were selected in the presence of the neomycin analogue G418 (500 g͞ml). For immunocytochemistry, cells were fixed with 3.7% (vol͞vol) formaldehyde in PBS and permeabilized with 0.1% Triton X-100. They were then incubated with mouse monoclonal antiRho A (Santa Cruz Biotechnology), and anti-p21 (PharMingen) for 1 h. After washing the cells with PBS, rhodamine-conjugated goat anti-mouse IgG and fluorescein-conjugated goat antimouse IgG (Zymed) were individually added in different wells for 1 h. Cells then were washed with PBS and mounted onto glass slides and examined by a UV-light microscope equipped with epi-illumination.
Data Analysis. Band intensities were analyzed densitometrically with the Eagle Eye II system (Stratagene). All values were expressed as means Ϯ SE. Paired and unpaired student's t tests were used to determine the statistical significance.
Results
Effect of Simvastatin on HG-Induced DNA Synthesis. To determine the dose-response effect of simvastatin on HG-induced MC proliferation, HG-exposed cells were treated with increasing concentrations of simvastatin (1, 5, and 10 M) for 24 h (Fig.  1A) . At 1 M concentration of simvastatin, DNA synthesis, as assessed by [ 3 H]thymidine incorporation, was reduced by 42 Ϯ 8% compared with cells grown in HG media. Cotreatment with 5 and 10 M of simvastatin reduced the DNA synthesis by 65 Ϯ 5% and 77 Ϯ 3%, respectively (P Ͻ 0.05). The [ 3 H]thymidine incorporation under basal conditions (normal glucose) was 51.8 Ϯ 4.5% (P Ͻ 0.05), relative to cells incubated in HG milieu.
To assess whether the effect of simvastatin on HG-induced proliferation can be ameliorated by mevalonate, the cells were exposed to NG (5 mM 
Effect of HG and Simvastatin on Cell-Cycle Regulatory Proteins.
To determine the modulatory effect of simvastatin on cell-cycle regulatory proteins in HG-induced proliferating MCs, the effect of simvastatin on CDK inhibitors p21 and p27, as well as in cyclin D1 and cyclin A, was investigated. HG exposure decreased p21 protein expression significantly as compared with NG after 6, 12, and 24 h to 59 Ϯ 26%, 17 Ϯ 9%, and 29 Ϯ 10%, respectively, as assessed by Western blot analyses ( Fig. 2A) . Cotreatment with simvastatin reversed the down-regulation of p21, resulting in a significant increase in p21 protein expression after 6, 12, and 24 h of treatment to 178 Ϯ 46%, 77 Ϯ 13%, and 76 Ϯ 13% (respectively) compared with NG (Fig. 2 A) . In contrast, protein levels of p27, cyclin D1, and cyclin A were not significantly changed with HG exposure (Fig. 2B) .
Effect of HG and Simvastatin on CDK Activity. To determine whether simvastatin can reverse the effects of HG on CDK activity, the effect of simvastatin on CDK4 and CDK2 activities was investigated. By using GST-Rb fusion protein as a substrate for CDK4 activity and histone H1 for CDK2 activity, the HG treatment increased CDK4 and CDK2 activities by 6-and 2-fold, respectively. Cotreatment with simvastatin reversed CDK4 activity reducing it by almost four-fold (Fig. 3a) . However, simvastatin reversed CDK2 activity to a very limited extent (Fig. 3b) .
Effect of HG and Simvastatin on Ras and Rho Membrane Translocation.
Small GTPases of the Ra and Rho family have been shown to regulate the cell-cycle progression (11, 20, 21) . To investigate the role of small GTPase in HG-induced proliferation of MCs, cells were exposed to HG milieu, and total amount and membraneassociated proteins of Ras and Rho GTPases were determined. HG treatment increased the protein expression of membraneassociated Ras by Ϸthree-fold in MCs without any discernible change in the total amount of cellular Ras GTPase (Fig. 4A) . HG stimulation also caused an Ϸ3-fold increase in the protein expression of membrane-associated Rho GTPase without significantly affecting the total amount of Rho (Fig. 4B) . Cotreatment with simvastatin reversed HG-induced increase in the Ras and Rho membrane-associated protein expression (Figs.  4 A and B) .
Relevance of Rho GTPase in HG-Induced DNA Synthesis. It has been shown previously that Rho geranylgeranylation is required for its membrane-associated GTPase activity (9, 10) . To determine the role of Rho geranylgeranylation in HG-induced DNA synthesis, cells were treated with various isoprenoids, including FFP, GGPP, and squalene. Treatment with GGPP (5 M) almost completely reversed (86 Ϯ 8%) the inhibitory effect of simvastatin in MCs exposed to HG, as assessed by [ 3 H]thymidine incorporation (Fig. 5) , whereas the treatment with FFP (5 M) did not reverse the simvastatin-induced decrease of DNA synthesis in cells exposed to HG. Also, the treatment with squalene (5 M) failed to reverse the simvastatin-induced decrease of DNA synthesis (data not shown).
To establish a direct role of Rho GTPase in the HG-induced down-regulation of p21, MCs maintained in HG media were individually transfected with a wtRhoA and a dominant-negative RhoA (N19RhoA mutant); the latter acts by competitively inhibiting the interaction of endogenous RhoA with its exchange factors. The MCs transfected with the N19RhoA mutant showed (Fig. 6) . All experiments were performed in triplicate and were repeated two times.
Discussion
This study indicates that statins inhibit HG-induced MC proliferation by preventing geranylgeranylation of Rho GTPase and by reversing Rho GTPase-induced down-regulation of CDKinhibitor p21. The ability to inhibit MC proliferation indicates that statins may have beneficial effects beyond their cholesterollowering properties in early diabetic nephropathy. The findings also suggest the involvement of a previously uncharacterized Rho-dependent intracellular signaling pathway in HG-induced proliferation of MC (Fig. 7) . In recent years, it has become increasingly clear that the HG-signaling pathway is cell specific (22). The deleterious effects of hyperglycemia are characteristically observed in cells and tissues that do not depend on insulin for glucose entry, and, hence, are not capable of down-regulating the HG-signaling pathway, as in neuronal, retinal, and renal cells (23) . Regarding the MC response to the HG ambience, a number of studies have investigated various signaling pathways in glomerular MCs that are affected in response to HG (24) (25) (26) (27) . This study indicates that a Rho͞p21-dependent signaling pathway is involved in the HG-induced proliferation of MCs, which is seen in the early stages of diabetic nephropathy. The data presented in this study also is consistent with previous reports of a possible relationship between the Rho GTPase signaling pathway and cell-cycle regulatory proteins (28) (29) (30) (31) . For instance, an increased expression and activity of RhoA has been associated with reduced p27 expression in the vasculature of hypertensive rats (28) . Rho GTPase also has been shown to be crucial for cyclin D1 expression in G 1 phase of the cell cycle in NIH 3T3 cells (29) . Similarly, Olson et al. (30) have reported that RhoA is required for the serum-dependent inhibition of p21 that occurs in Swiss 3T3 cells microinjected with H-Ras V12 (30) . These results seem to indicate that the correlation between the Rho GTPase signaling pathway and different cell-cycle regulatory proteins is cell specific and possibly growth factor dependent. Data presented in this study extend these observations by demonstrating that exposure of MCs to HG environment activates the Rho GTPase signaling pathway by stimulating CDK2 and CDK4 kinase activity and by down-regulating the CDK inhibitor, p21. The concomitant activation of Ras and Rho by HG also is consistent with previous studies suggesting a possible relationship between Ras and Rho GTPase proteins, where the activation of RhoA was elucidated as a downstream effect of activated Ras (31, 32) .
With respect to the biological effects of statins relative to Rho GTPase and cell-cycle proteins, Laufs et al. (7) have shown an increase in RhoA GTPase activity in platelet-derived growth factor (PDGF)-induced vascular smooth muscle cells (VSMC) that was attenuated with simvastatin treatment. Similarly, upregulation of transforming growth factor-␤ in cultured heart cells by statins have been reported to be associated with the inhibition of the RhoA GTPase signaling pathway (8) . Moreover, it has been shown that a dominant-negative mutant of RhoA is associated with increased levels of p27 in VSMCs stimulated with PDGF (7). Another HMG-CoA reductase inhibitor, lovastatin, has been shown to increase the levels of p21 in prostate cancer cells (33) . These differences could be cell specific, but they indicate a direct correlation between the Rho GTPase pathway and CDK inhibitors p21 and p27, albeit their roles may vary in different disease processes. In our study, the finding of overexpression of a dominant-negative Rho mutant (N19RhoA) mimicking the effect of simvastatin on p21 protein expression supports the contention of activation of a Rho GTPase͞p21-simvastatin-inhibitable pathway by HG. In regard to the cholesterol-independent ''pleiotropic'' effects of statins, they are most likely mediated through inhibition of Rho geranylgeranylation. Moreover, geranylgeranylation, and not farnesylation, has been reported to be primarily responsible for releasing the G 1 ͞S phase block (34) . This observation is consistent with our findings that in the presence of simvastatin, addition of GGPP, but not FPP, restored the higher rate of DNA synthesis under the influence of HG ambience.
In support of the judicious use of statins, the initial clinical studies on the effects of statins on the progression of diabetic nephropathy were encouraging (35) (36) (37) . In a study from Hong Kong (36) , it was suggested that despite no significant effect on proteinuria, a decline in renal function was attenuated by lovastatin. In another crossover study with simvastatin, a significant decrease in proteinuria in type 2 diabetic patients was observed (37) . Initially, the beneficial effects of statins were attributed solely to improved lipid alterations in the renal cortical tissue and decreased lipid-induced accumulation of the macrophages in the kidneys, because high levels of plasma low density lipoprotein cholesterol, triglycerides, and apolipoprotein B are seen in patients with diabetic nephropathy. However, this study provides a new rationale for the use of statins in the early stages of diabetic nephropathy, independently of their cholesterol-lowering properties. Finally, the findings of this study should give impetus for future investigations to study the effects of statins in the prevention of nephropathy in diabetic patients.
